Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept long-term safety rollover study
2022-502498-40-00Phase 3Authorised
- Sponsor
- Celgene Corporation
- Start
- Jul 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 3, open-label trial of luspatercept in myelodysplastic syndrome (MDS), beta thalassemia and myelofibrosis (MF) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Adverse events, Progression to high/very high-risk myelodysplastic syndrome and 2 more. Planned start Jul 2019; status: authorised.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)beta thalassemiamyelofibrosis (MF)
Beyond the preview
Go deeper on 2022-502498-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502498-40-00.